MARKET

PRLD

PRLD

Prelude Therapeutics Inc
NASDAQ
2.170
+0.150
+7.43%
After Hours: 2.080 -0.09 -4.15% 17:32 02/06 EST
OPEN
2.070
PREV CLOSE
2.020
HIGH
2.210
LOW
1.980
VOLUME
221.75K
TURNOVER
--
52 WEEK HIGH
4.220
52 WEEK LOW
0.6101
MARKET CAP
136.42M
P/E (TTM)
-1.4752
1D
5D
1M
3M
1Y
5Y
1D
BUZZ-U.S. STOCKS ON THE MOVE-Allurion, Rithm Capital, Medtronic
Reuters · 5d ago
Prelude Therapeutics Gains on FDA Greenlight for Phase 1 Blood-Cancer Drug Trial
Dow Jones · 5d ago
Prelude climbs as FDA clears study for Incyte-partnered cancer candidate
Seeking Alpha · 5d ago
BUZZ-U.S. STOCKS ON THE MOVE-Western Digital, Broadridge, WTW
Reuters · 5d ago
BUZZ-Prelude Therapeutics rises after FDA clears early-stage trial of blood cancer drug
Reuters · 5d ago
Prelude Therapeutics Wins FDA IND Clearance for PRT12396
TipRanks · 5d ago
Prelude receives FDA clearance for investigational IND for PRT12396
TipRanks · 5d ago
FDA Clears Prelude Therapeutics' IND Application for JAK2V617F Inhibitor PRT12396
Reuters · 5d ago
More
About PRLD
Prelude Therapeutics Incorporated is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. It has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT7732. PRT3789 is a highly selective degrader of SMARCA2 protein, which, along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT2527 is designed to be a potent and selective CDK9 inhibitor that has the potential to avoid off-target toxicities observed with other less selective CDK9 inhibitor. PRT7732 is a highly selective and orally bioavailable SMARCA2 degrader.

Webull offers Prelude Therapeutics Inc stock information, including NASDAQ: PRLD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRLD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PRLD stock methods without spending real money on the virtual paper trading platform.